- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy
- Diagnostic Test · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 985–1008
of 4,663
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Lung Cancer
- Interventions
- topotecan hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1993
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sinusitis, Acute
- Interventions
- Amoxicillin 875 mg, Placebo (lactase)
- Drug · Dietary Supplement
- Lead sponsor
- Paul Sorum, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Cohoes, New York
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Chemotherapy, Pembrolizumab, Ramucirumab
- Drug · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 838 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 566
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Web-based Access to CPAP Data, Web-based Access to CPAP Data with Financial Incentive
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Wynnewood, Pennsylvania
- Conditions
- Lung Cancer
- Interventions
- pemetrexed disodium, sorafenib tosylate
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 207
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 124 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
- Drug · Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 497 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Medford, Oregon • Greenville, South Carolina • Spartanburg, South Carolina
- Conditions
- Cystic Fibrosis
- Interventions
- ELX/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 13
- States / cities
- Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
- Conditions
- Headache, Migraine
- Interventions
- Tx360
- Device
- Lead sponsor
- Tian Medical Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 11
- States / cities
- New Haven, Connecticut • Stamford, Connecticut • Fort Gordon, Georgia + 8 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Placebo, Cisplatin
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Fullerton, California + 46 more
- Conditions
- COVID-19
- Interventions
- Nitazoxanide, Placebo, Vitamin Super B-Complex
- Drug · Dietary Supplement
- Lead sponsor
- Romark Laboratories L.C.
- Industry
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Fort Lauderdale, Florida • The Bronx, New York
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Fluticasone propionate, Flonase®, Placebo
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- GW685698X aqueous nasal spray
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Early Ventilator Associated Pneumonia
- Interventions
- Default 4 days antibiotic therapy
- Drug
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Advanced NSCLC, Metastatic Lung Cancer
- Interventions
- Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin
- Drug · Combination Product
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 59
- States / cities
- Fountain Valley, California • Fullerton, California • San Francisco, California + 45 more
- Conditions
- Recurrent Non-small Cell Lung Cancer
- Interventions
- triapine, gemcitabine hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Spasmodic Dysphonia
- Interventions
- Zinc gluconate supplement, Botulinum toxin type A
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- SARS-CoV-2
- Interventions
- Upamostat, Placebo (PO)
- Drug
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
- Conditions
- Chemotherapy-induced Thrombocytopenia
- Interventions
- Romiplostim, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Ogden, Utah • Spokane, Washington
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
- Interventions
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 82
- States / cities
- Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Aldesleukin, Pembrolizumab
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
- Interventions
- Beta-lactam antibiotic, Aminoglycoside
- Drug
- Lead sponsor
- Chris Goss
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 49 more